300896 爱美客
已收盘 08-01 15:00:00
资讯
新帖
简况
爱美客:截至2025年7月31日公司股东人数为55,143户
证券之星 · 08-01 07:07
爱美客:截至2025年7月31日公司股东人数为55,143户
爱美客:嗗科拉市场定价为33,800元/1ml
证券之星 · 08-01 07:04
爱美客:嗗科拉市场定价为33,800元/1ml
爱美客和江苏吴中“童颜针”纠纷:一场关于利润与渠道的争夺战
蓝鲸财经 · 07-31
爱美客和江苏吴中“童颜针”纠纷:一场关于利润与渠道的争夺战
爱美客:持续建立健全内部管理体系
证券之星 · 07-28
爱美客:持续建立健全内部管理体系
中金:爱美客并购AESTHEFILL迎积极进展,维持“跑赢行业”评级
格隆汇 · 07-25
中金:爱美客并购AESTHEFILL迎积极进展,维持“跑赢行业”评级
“童颜针”代理权如何界定?爱美客称江苏吴中事实上构成违约,解约后将启用新商标
澎湃新闻 · 07-22
“童颜针”代理权如何界定?爱美客称江苏吴中事实上构成违约,解约后将启用新商标
爱美客押注Regen难抢“童颜针”生意,*ST苏吴艾塑菲代理权归属明确至2032年且获双“保障”
证券之星 · 07-18
爱美客押注Regen难抢“童颜针”生意,*ST苏吴艾塑菲代理权归属明确至2032年且获双“保障”
爱美客:有关业绩预告的相关情况
证券之星 · 07-16
爱美客:有关业绩预告的相关情况
2025年中国医美注射材料细分市场分析之医美注射类玻尿酸 2024年市场规模约125亿元【组图】
前瞻产业研究院 · 07-16
2025年中国医美注射材料细分市场分析之医美注射类玻尿酸 2024年市场规模约125亿元【组图】
爱美客:公司未涉及原料药领域
证券之星 · 07-10
爱美客:公司未涉及原料药领域
业绩高增长不再,A股医美龙头爱美客股价承压被基金机构减持,营收净利增速首降至个位数
市场资讯 · 07-09
业绩高增长不再,A股医美龙头爱美客股价承压被基金机构减持,营收净利增速首降至个位数
爱美客公布国际专利申请:“一种可注射的互锁交联透明质酸或其盐水凝胶、制备方法及应用”
证券之星 · 07-04
爱美客公布国际专利申请:“一种可注射的互锁交联透明质酸或其盐水凝胶、制备方法及应用”
中证全指医疗器械指数上涨0.13%,前十大权重包含爱美客等
金融界 · 07-03
中证全指医疗器械指数上涨0.13%,前十大权重包含爱美客等
2025年中国医美注射材料细分市场分析之医美注射类胶原蛋白 2024年市场规模约67亿元【组图】
前瞻产业研究院 · 07-01
2025年中国医美注射材料细分市场分析之医美注射类胶原蛋白 2024年市场规模约67亿元【组图】
爱美客:截至2025年6月30日公司股东人数为58,235户
证券之星 · 07-01
爱美客:截至2025年6月30日公司股东人数为58,235户
爱美客:肉毒毒素项目正按要求补充资料
证券之星 · 06-27
爱美客:肉毒毒素项目正按要求补充资料
爱美客:公司Ⅲ类医疗器械产品上市需严格注册审批
证券之星 · 06-27
爱美客:公司Ⅲ类医疗器械产品上市需严格注册审批
2025年中国玻尿酸三巨头经营密码分析:昊海生科“投资并购”助推医美,华熙生物全产业链覆盖,爱美客聚焦医美
前瞻产业研究院 · 06-24
2025年中国玻尿酸三巨头经营密码分析:昊海生科“投资并购”助推医美,华熙生物全产业链覆盖,爱美客聚焦医美
爱美客:探索胶原蛋白产品应用领域更多市场机会
证券之星 · 06-23
爱美客:探索胶原蛋白产品应用领域更多市场机会
爱美客:公司账面上存在部分证券投资主要原因系并购或战略投资引起
证券之星 · 06-23
爱美客:公司账面上存在部分证券投资主要原因系并购或战略投资引起
加载更多
公司概况
公司名称:
爱美客技术发展股份有限公司
所属行业:
专用设备制造业
上市日期:
2020-09-28
主营业务:
爱美客技术发展股份有限公司的主营业务是生物医用材料及生物医药产品研发与转化。公司的主要产品是医用含聚乙烯醇凝胶微球的透明质酸钠-羟丙基甲基纤维素凝胶、注射用修饰透明质酸钠凝胶、医用透明质酸钠-羟丙基甲基纤维素凝胶、含左旋乳酸-乙二醇共聚物微球的交联透明质酸钠凝胶、注射用透明质酸钠复合溶液、医用羟丙基甲基纤维素-透明质酸钠溶液、聚对二氧环己酮面部埋植线。公司已拥有八款获得国家药监局批准的Ⅲ类医疗器械产品,是国内获得国家药监局认证用于非手术医疗美容Ⅲ类医疗器械数量最多的企业。
发行价格:
118.27
{"stockData":{"symbol":"300896","market":"SZ","secType":"STK","nameCN":"爱美客","latestPrice":184.53,"timestamp":1754031795000,"preClose":184.9,"halted":0,"volume":2324188,"delay":0,"changeRate":-0.002,"floatShares":209000000,"shares":303000000,"eps":6.1929,"marketStatus":"已收盘","change":-0.37,"latestTime":"08-01 15:00:00","open":185.2,"high":187.97,"low":183.51,"amount":431000000,"amplitude":0.0241,"askPrice":184.8,"askSize":1,"bidPrice":184.53,"bidSize":45,"shortable":0,"etf":0,"ttmEps":6.1929,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1754271000000},"marketStatusCode":5,"adr":0,"adjPreClose":184.9,"symbolType":"stock","openAndCloseTimeList":[[1754011800000,1754019000000],[1754024400000,1754031600000]],"highLimit":203.39,"lowLimit":166.41,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":302592061,"isCdr":false,"pbRate":6.79,"roa":"--","peRate":29.797026,"roe":"5.53%","epsLYR":6.5,"committee":0.493671,"marketValue":55837000000,"turnoverRate":0.0111,"status":1,"floatMarketCap":38491000000},"requestUrl":"/m/hq/s/300896","defaultTab":"news","newsList":[{"id":"2556086224","title":"爱美客:截至2025年7月31日公司股东人数为55,143户","url":"https://stock-news.laohu8.com/highlight/detail?id=2556086224","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556086224?lang=zh_cn&edition=full","pubTime":"2025-08-01 15:07","pubTimestamp":1754032038,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客(300896)08月01日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2025年七月 31日公司的股东总数是多少?谢谢爱美客回复:尊敬的投资者您好,截至2025年7月31日,公司股东人数为55,143户。感谢您对公司的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080100019904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300896","BK0251"],"gpt_icon":0},{"id":"2556862215","title":"爱美客:嗗科拉市场定价为33,800元/1ml","url":"https://stock-news.laohu8.com/highlight/detail?id=2556862215","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556862215?lang=zh_cn&edition=full","pubTime":"2025-08-01 15:04","pubTimestamp":1754031876,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客(300896)08月01日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,公司新品嗗科拉自5月份上市,请问目前市场定价是多少?今年的销售目标怎么样?跟宝尼达对比,有哪些优势?谢谢爱美客回复:尊敬的投资者您好,嗗科拉产品目前市场定价为33,800元/1ml。嗗科拉是公司推出的全新材料研发框架下的组织仿生材料,与宝尼达相比较,两款产品的产品线、产品定位及适应症等方面均存在差异,可以满足不同消费群体的需求。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080100019867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300896","BK0251"],"gpt_icon":0},{"id":"2555988609","title":"爱美客和江苏吴中“童颜针”纠纷:一场关于利润与渠道的争夺战","url":"https://stock-news.laohu8.com/highlight/detail?id=2555988609","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555988609?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:39","pubTimestamp":1753951149,"startTime":"0","endTime":"0","summary":"今年7月,江苏吴中公告称孙公司达透医疗收到韩国Regen发来的《解约函》,单方面解除对“童颜针”产品艾塑菲在中国境内的独家经销协议。同时,吴中美学的唯一股东江苏吴中及高管严重违反证券法被行政处罚,严重影响了艾塑菲的品牌声誉。3个月后,Regen完成董事会改选,这意味着,爱美客成为其实际控制人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507311654269729b2e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507311654269729b2e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0012","BK0060","BK0239","BK0251","300896","BK0028","600200"],"gpt_icon":0},{"id":"2554725434","title":"爱美客:持续建立健全内部管理体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2554725434","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554725434?lang=zh_cn&edition=full","pubTime":"2025-07-28 15:09","pubTimestamp":1753686555,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客07月28日在投资者关系平台上答复投资者关心的问题。许多竞争对手的利益相关方,这时候可能在暗查爱美客的财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072800014124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300896","BK0251"],"gpt_icon":0},{"id":"2554680647","title":"中金:爱美客并购AESTHEFILL迎积极进展,维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2554680647","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554680647?lang=zh_cn&edition=full","pubTime":"2025-07-25 16:09","pubTimestamp":1753430971,"startTime":"0","endTime":"0","summary":"中金公司研报指出,爱美客并购AESTHEFILL迎积极进展,关注后续整合节奏。认为进展标志着公司收购AestheFill的整合协同顺利推进,看好公司借助本次并购实现业绩增厚和全球化拓展的广阔成长前景。认为后续两款产品有望与公司自有的凝胶类产品濡白天使形成补充,丰富再生类产品矩阵,并借助Regen广泛的全球分销体系与爱美客的渠道运营经验,进一步打开全球市场。此外,看好公司后续多管线逐步落地的广阔成长空间。维持“跑赢行业”评级及目标价248元,。\n\n\r\n 责任编辑:小讯","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2025/07/25160951980428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["300896"],"gpt_icon":0},{"id":"2553230430","title":"“童颜针”代理权如何界定?爱美客称江苏吴中事实上构成违约,解约后将启用新商标","url":"https://stock-news.laohu8.com/highlight/detail?id=2553230430","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553230430?lang=zh_cn&edition=full","pubTime":"2025-07-22 18:48","pubTimestamp":1753181330,"startTime":"0","endTime":"0","summary":"对于此次解约,7月21日晚间,江苏吴中在一份公开声明将矛头指向了爱美客,称解约函彻底背离了之前双方签订的独家经销协议、Regen公司书面承诺和Regen公司控制方爱美客公司的公开表态,严重破坏商业伦理。对于江苏吴中的声明,爱美客强调,一切以事实依据和法律依据为准。此次代理权的争议将直接影响江苏吴中接下来的业绩。对于更改注册证代理人名称,江苏吴中在21日的声明中称,Regen公司违约在先。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722190018954ccb37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722190018954ccb37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","600200","BK0060","300896","BK0239","BK0251","BK0012","BK0188"],"gpt_icon":0},{"id":"2552445562","title":"爱美客押注Regen难抢“童颜针”生意,*ST苏吴艾塑菲代理权归属明确至2032年且获双“保障”","url":"https://stock-news.laohu8.com/highlight/detail?id=2552445562","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552445562?lang=zh_cn&edition=full","pubTime":"2025-07-18 10:25","pubTimestamp":1752805509,"startTime":"0","endTime":"0","summary":"7月17日晚间,*ST苏吴发布公告称,达透医疗拥有艾塑菲在中国境内的独家代理权有效期至2032年8月28日。证券之星注意到,今年3月10日,爱美客正式官宣拟以1.9亿美元收购韩国Regen公司,此事随即引发市场关于艾塑菲国内代理权的舆论热议。一旦Regen与*ST苏吴因代理权对簿公堂,艾塑菲将瞬间沦为“争议产品”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025071800010927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0188","BK0239","600200","BK0012","300896","BK0060","BK0028"],"gpt_icon":0},{"id":"2551129934","title":"爱美客:有关业绩预告的相关情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2551129934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551129934?lang=zh_cn&edition=full","pubTime":"2025-07-16 23:12","pubTimestamp":1752678733,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客(300896)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问:吸收合并韩国公司,今年中报利润如果有大幅度变化,会不会发预告。爱美客回复:尊敬的投资者您好,有关业绩预告的相关情况,公司严格按照《深圳证券交易所创业板股票上市规则》相关规定进行披露,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600038371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300896"],"gpt_icon":0},{"id":"2551114813","title":"2025年中国医美注射材料细分市场分析之医美注射类玻尿酸 2024年市场规模约125亿元【组图】","url":"https://stock-news.laohu8.com/highlight/detail?id=2551114813","media":"前瞻产业研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551114813?lang=zh_cn&edition=full","pubTime":"2025-07-16 12:00","pubTimestamp":1752638441,"startTime":"0","endTime":"0","summary":"2、医美注射类玻尿酸市场规模玻尿酸是最早规模化应用的医美注射材料,消费者认知度,2024年,我国医美注射类玻尿酸市场规模约125亿元,同比增长21.4%,2021-2024年CAGR为25.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716120609954458bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716120609954458bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","300896","688366","688363","02367","BK0251","BK0239"],"gpt_icon":0},{"id":"2550861370","title":"爱美客:公司未涉及原料药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2550861370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550861370?lang=zh_cn&edition=full","pubTime":"2025-07-10 15:09","pubTimestamp":1752131353,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客07月10日在投资者关系平台上答复投资者关心的问题。国内出口原料药到美国,通常需要通过美国FDA的现场审核。公司始终专注于终端产品的开发,目前未涉及原料药领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000018288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300896"],"gpt_icon":0},{"id":"2550467656","title":"业绩高增长不再,A股医美龙头爱美客股价承压被基金机构减持,营收净利增速首降至个位数","url":"https://stock-news.laohu8.com/highlight/detail?id=2550467656","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550467656?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:16","pubTimestamp":1752070560,"startTime":"0","endTime":"0","summary":" 曾被冠以“医美茅台”之称的爱美客,凭借超高毛利率和强劲增速在资本市场书写传奇。 然而,潮峰投研注意到,爱美客近年来起股价一路走低,从最高500多元每股跌至7月9日收盘的171元每股,华宝基金等机构今年一季度进行了股份减持。营收净利首次双位数增长告破回归至个位数。 2024年,爱美客的业绩增长显著失速。 这是自2016年以来,公司年度营收和净利润增速首次降至个位数。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-07-09/doc-infewutk9314858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300896","159982","399300"],"gpt_icon":0},{"id":"2549031580","title":"爱美客公布国际专利申请:“一种可注射的互锁交联透明质酸或其盐水凝胶、制备方法及应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2549031580","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549031580?lang=zh_cn&edition=full","pubTime":"2025-07-05 05:07","pubTimestamp":1751663222,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示爱美客(300896)公布了一项国际专利申请,专利名为“一种可注射的互锁交联透明质酸或其盐水凝胶、制备方法及应用”,专利申请号为PCT/CN2024/139963,国际公布日为2025年7月3日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来爱美客已公布的国际专利申请3个,较去年同期增加了50%。结合公司2024年年报财务数据,2024年公司在研发方面投入了3.04亿元,同比增21.41%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070500005188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300896"],"gpt_icon":0},{"id":"2548383192","title":"中证全指医疗器械指数上涨0.13%,前十大权重包含爱美客等","url":"https://stock-news.laohu8.com/highlight/detail?id=2548383192","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548383192?lang=zh_cn&edition=full","pubTime":"2025-07-03 22:45","pubTimestamp":1751553933,"startTime":"0","endTime":"0","summary":"数据统计显示,中证全指医疗器械指数,近三个月下跌3.19%,年至今下跌1.48%。从中证全指医疗器械指数持仓样本的行业来看,医药卫生占比100.00%。在样本公司有特殊事件发生,导致其行业归属发生变更时,将对中证全指行业指数样本进行相应调整。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/03224551469508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159883","BK1100","BK1583","09996","BK1574","BK1222","000985.SH","300896","09997","BK0251"],"gpt_icon":0},{"id":"2548747030","title":"2025年中国医美注射材料细分市场分析之医美注射类胶原蛋白 2024年市场规模约67亿元【组图】","url":"https://stock-news.laohu8.com/highlight/detail?id=2548747030","media":"前瞻产业研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548747030?lang=zh_cn&edition=full","pubTime":"2025-07-01 16:00","pubTimestamp":1751356857,"startTime":"0","endTime":"0","summary":"2、医美注射类胶原蛋白市场规模胶原蛋白是人体自身存在的物质,与人体组织的相容性高,不易引起排异反应和过敏现象,2024年,我国医美注射类胶原蛋白市场规模约67亿元,同比增长21.8%,2021-2024年CAGR为21.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507011705429795b0e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507011705429795b0e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","02367","BK0229","BK0239","688366","688363","300896"],"gpt_icon":0},{"id":"2548314020","title":"爱美客:截至2025年6月30日公司股东人数为58,235户","url":"https://stock-news.laohu8.com/highlight/detail?id=2548314020","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548314020?lang=zh_cn&edition=full","pubTime":"2025-07-01 15:03","pubTimestamp":1751353430,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客(300896)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2025年六月 30日公司的股东总数是多少?谢谢爱美客回复:尊敬的投资者您好,截至2025年6月30日,公司股东人数为58,235户。感谢您对公司的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100019940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300896","BK0251"],"gpt_icon":0},{"id":"2546479041","title":"爱美客:肉毒毒素项目正按要求补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2546479041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546479041?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:30","pubTimestamp":1751013059,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客(300896)06月27日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司肉毒素项目进展如何?三季度能否投入市场,谢谢爱美客回复:尊敬的投资者您好,公司肉毒毒素项目正在按国家药品监督管理局药品审评中心要求补充资料,注册批件审评时间及结果需以国家药监局审评结果为准。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062700026808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300896"],"gpt_icon":0},{"id":"2546462790","title":"爱美客:公司Ⅲ类医疗器械产品上市需严格注册审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2546462790","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546462790?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:30","pubTimestamp":1751013057,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客(300896)06月27日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵司是如何看待社交媒体中出现避雷嗨体,用后无效和不打脖子在别处超范使用的情况?是否可以超范使用?爱美客回复:尊敬的投资者您好,公司Ⅲ类医疗器械产品上市需要经过严格的注册和审批程序,以保证安全性和有效性,客户在使用时应严格遵守说明书的指导。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062700026804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1222","09997","300896","159883","BK1100","BK0251","BK1574","09996","BK1583"],"gpt_icon":0},{"id":"2545240857","title":"2025年中国玻尿酸三巨头经营密码分析:昊海生科“投资并购”助推医美,华熙生物全产业链覆盖,爱美客聚焦医美","url":"https://stock-news.laohu8.com/highlight/detail?id=2545240857","media":"前瞻产业研究院","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545240857?lang=zh_cn&edition=full","pubTime":"2025-06-24 15:00","pubTimestamp":1750748411,"startTime":"0","endTime":"0","summary":"根据公司公告,2024年,昊海生科已形成医疗美容与创面护理、眼科、骨科以及防粘连及止血四大业务板块,分别占总营收的44.28%、31.79%、16.93%以及5.41%。从增长幅度来看,医美无疑是昊海生科的四个业务板块中表现最为突出,2024年昊海生科医疗美容与创面护理营收达11.95亿元,同比增长13.06%,2020至2024年CAGR为49.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624150550978c6be5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624150550978c6be5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","300896","688366","688363","BK0251","BK0239"],"gpt_icon":0},{"id":"2545493077","title":"爱美客:探索胶原蛋白产品应用领域更多市场机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2545493077","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545493077?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:11","pubTimestamp":1750666269,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客06月23日在投资者关系平台上答复投资者关心的问题。未来公司将探索胶原蛋白产品应用领域的更多市场机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062300017562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300896"],"gpt_icon":0},{"id":"2545493051","title":"爱美客:公司账面上存在部分证券投资主要原因系并购或战略投资引起","url":"https://stock-news.laohu8.com/highlight/detail?id=2545493051","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545493051?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:10","pubTimestamp":1750666251,"startTime":"0","endTime":"0","summary":"证券之星消息,爱美客(300896)06月23日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司作为一家创新企业,为什么会对证券投资这样情有独钟,并且亏损累累,尤其是对博安生物的投资,亏损严重,请贵公司做一个合理的解释爱美客回复:尊敬的投资者您好,公司账面上存在部分证券投资主要原因系并购或战略投资引起。公司在并购哈尔滨沛奇隆生物制药有限公司前,该公司账上即存在持有证券的情况;公司对博安生物的投资在上市之前,属于战略投资。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062300017527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","161027","300896"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1754264087041,"stockEarnings":[{"period":"1week","weight":-0.0367},{"period":"1month","weight":0.0731},{"period":"3month","weight":0.0666},{"period":"6month","weight":0.1093},{"period":"1year","weight":0.0903},{"period":"ytd","weight":0.0335}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.0857},{"period":"6month","weight":0.0952},{"period":"1year","weight":0.214},{"period":"ytd","weight":0.0621}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"爱美客技术发展股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"55143人(较上一季度减少3.87%)","perCapita":"3782股","listingDate":"2020-09-28","address":"北京市昌平区科技园区白浮泉路10号北控科技大厦4层416B室","registeredCapital":"30259万元","survey":" 爱美客技术发展股份有限公司的主营业务是生物医用材料及生物医药产品研发与转化。公司的主要产品是医用含聚乙烯醇凝胶微球的透明质酸钠-羟丙基甲基纤维素凝胶、注射用修饰透明质酸钠凝胶、医用透明质酸钠-羟丙基甲基纤维素凝胶、含左旋乳酸-乙二醇共聚物微球的交联透明质酸钠凝胶、注射用透明质酸钠复合溶液、医用羟丙基甲基纤维素-透明质酸钠溶液、聚对二氧环己酮面部埋植线。公司已拥有八款获得国家药监局批准的Ⅲ类医疗器械产品,是国内获得国家药监局认证用于非手术医疗美容Ⅲ类医疗器械数量最多的企业。","listedPrice":118.27},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"爱美客(300896)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供爱美客(300896)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"爱美客,300896,爱美客股票,爱美客股票老虎,爱美客股票老虎国际,爱美客行情,爱美客股票行情,爱美客股价,爱美客股市,爱美客股票价格,爱美客股票交易,爱美客股票购买,爱美客股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"爱美客(300896)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供爱美客(300896)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}